Back to Top Skip to main content Skip to sub-navigation

DOD Pharmacy & Therapeutics Committee

The Department of Defense Pharmacy & Therapeutics (DOD P&T) Committee's mission is to uniformly, consistently, and equitably provide appropriate drug therapy to meet the clinical needs of DOD beneficiaries in an effective, efficient, and fiscally responsible manner.

To learn more, please see the Dec. 2004 Health Affairs Policy 04-032, TRICARE Pharmacy Benefit Formulary Management (clarified March 22, 2005).

DOD P&T Committee Meeting Schedule

View DOD P&T Meeting Minutes See Archived Meeting Pages


Aug. 3-4, 2022

Uniform Formulary Request for Quote Information (Class Review)

  • UF BPA & UF ADP RFQ Documents Posted: April 22, 2022
  • Pre-Proposal Teleconference: May 11, 2022
  • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
  • UF BPA & UF ADP Class Quotes Due: June 9, 2022

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • ANTIDEPRESSANTS AND NON-OPIOID PAIN SYNDROME AGENTS - GAMMA-AMINOBUTYRIC ACID ANALOGS:
    • Gralise
    • Horizant
  • ANTIDEPRESSANTS AND NON-OPIOID PAIN SYNDROME AGENTS - NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITORS:
    • Aplenzin
  • ANTIDEPRESSANTS AND NON-OPIOID PAIN SYNDROME AGENTS - SELECTIVE SEROTONIN REUPTAKE INHIBITORS:
    • Pexeva
    • Trintellix
    • Viibryd
  • ANTIDEPRESSANTS AND NON-OPIOID PAIN SYNDROME AGENTS - SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS:
    • Drizalma
    • Fetzima
    • Savella
  • OVERACTIVE BLADDER AGENTS - BETA-3 ADRENERGIC AGONISTS:
    • Gemtesa
    • Myrbetriq
    • Myrbetriq Granules

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

 

May 4-5, 2022

Uniform Formulary Request for Quote Information (Class Review)

  • UF BPA & UF ADP RFQ Documents Posted: Jan. 21, 2022
  • Pre-Proposal Teleconference: Feb. 2, 2022
  • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)
  • UF BPA & UF ADP Class Quotes Due: March 18, 2022

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • DIABETES NON INSULIN – GLP-1 AGONISTS INJECTABLE:
    • Bydureon Bcise
    • Byetta
    • Ozempic
    • Trulicity
    • Victoza
  • MIGRAINE AGENTS – ORAL CGRP:
    • Nurtec ODT
    • Qulipta
    • Ubrelvy

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

  • Adbry
  • Cibingo
  • Dartisla ODT
  • Fleqsuvy
  • Ibsrela
  • Pyrukynd
  • Recorlev
  • Releuko syr & vial
  • Seglentis
  • Soaanz
  • Tarpeyo
  • Twyneo
  • Vonjo
  • Zimhi


Feb. 9-10, 2022

Uniform Formulary Request for Quote Information (Class Review)

  • UF BPA & UF ADP RFQ Documents Posted: Oct. 26, 2021

  • Pre-Proposal Teleconference: Nov. 10, 2021

  • Clinical/Cost Presentation Meeting Window: (no clinical presentations requested)

  • UF BPA & UF ADP Class Quotes Due: Dec. 15, 2021

Class Review Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • BINDERS‐CHELATORS‐ANTIDOTES‐OVERDOSE AGENTS - HYPOGLYCEMIA AGENTS:
    • Baqsimi
    • Gvoke Hypopen
    • Gvoke Pre-Filled Syringe
    • Zegalogue Autoinjector
    • Zegalogue Syringe
  • ONCOLOGICAL AGENTS – MULTIPLE:
    • Afinitor Disperz
    • Cabometyx
    • Cometriq
    • Copiktra
    • Fotivda
    • Gilotrif
    • Inlyta
    • Inrebic
    • Iressa
    • Jakafi
    • Lenvima
    • Lynparza
    • Nexavar
    • Proleukin
    • Rubraca
    • Tagrisso
    • Talzenna
    • Venclexta
    • Venclexta Starting Pack
    • Vizimpro
    • Votrient
    • Zejula
    • Zortress
    • Zydelig

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

  • Besremi
  • Dhivy
  • Elyxyb
  • Eprontia
  • Livmarli
  • Livtencity
  • Qulipta
  • Scemblix
  • Skytrofa
  • Tyrvaya
  • Voxzogo
  • Tosymra

 


If the DOD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.


Subject to Change Disclaimer

The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.

Last Updated: May 06, 2022

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.